Biohaven Pharma (BHVN) presents update on degrader platform and summary of progress to date in Phase 1 single ascending dose study for BHV-1300

Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Biohaven+Pharma+%28BHVN%29+presents+update+on+degrader+platform+and+summary+of+progress+to+date+in+Phase+1+single+ascending+dose+study+for+BHV-1300/23065987.html for the full story.